Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review
- PMID: 20930103
- PMCID: PMC3227899
- DOI: 10.1634/theoncologist.2009-0331
Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review
Abstract
Objective: To compare the tolerability, efficacy, and safety profiles of pegylated liposomal doxorubicin in combination with carboplatin (PLD-Carbo) with those of gemcitabine-carboplatin (Gem-Carbo) for the treatment of patients with platinum-sensitive recurrent ovarian cancer (PSROC) by reviewing the published literature.
Methods: Using the PubMed database, a systematic review of peer-reviewed literature published between January 2000 and September 2009 was undertaken to identify studies related to the treatment of patients with PSROC with PLD-Carbo or Gem-Carbo. Studies reporting either response rate, progression-free survival (PFS), and/or overall survival (OS) were included. Treatment regimens, efficacy endpoints, and safety profiles were compared between the two combination therapies.
Results: Ten studies evaluating 608 patients (PLD-Carbo: 5 studies, 278 patients; Gem-Carbo: 5 studies, 330 patients) were identified. The mean planned doses were: PLD, 34.8 mg/m(2) and Gem, 993 mg/m(2). The dose intensity reported in Gem trials was lower (75% of the planned dose) than the dose intensity reported in PLD trials (93.7% of the planned dose), suggesting better tolerability for the PLD-Carbo regimen. Among patients receiving PLD-Carbo, 60.2% achieved a response (complete, 27.0%; partial, 33.2%), versus 51.4% of patients treated with Gem-Carbo (complete, 19.2%; partial, 32.2%). The median PFS times were 10.6 months and 8.9 months in the PLD-Carbo and the Gem-Carbo populations, respectively. The median OS was longer for the PLD-Carbo regimen (27.1 months) than for the Gem-Carbo regimen (19.7 months). The hematological safety profiles were comparable in the two groups, although grade III or IV anemia (PLD-Carbo, 13.6%; Gem-Carbo, 24.5%) and neutropenia (PLD-Carbo, 45.5%; Gem-Carbo, 62.9%) were more common in patients receiving Gem-Carbo.
Conclusion: Results from this systematic analysis of peer-reviewed literature suggest that PLD-Carbo therapy is a rational alternative to Gem-Carbo for the treatment of patients with PSROC.
Conflict of interest statement
The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.
Similar articles
-
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.Int J Clin Oncol. 2008 Apr;13(2):156-60. doi: 10.1007/s10147-007-0740-4. Epub 2008 May 8. Int J Clin Oncol. 2008. PMID: 18463961
-
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).Ann Oncol. 2016 Dec;27(12):2236-2241. doi: 10.1093/annonc/mdw418. Epub 2016 Oct 26. Ann Oncol. 2016. PMID: 27789470 Clinical Trial.
-
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).Gynecol Oncol. 2008 Jan;108(1):90-4. doi: 10.1016/j.ygyno.2007.08.075. Epub 2007 Oct 18. Gynecol Oncol. 2008. PMID: 17949799 Free PMC article. Clinical Trial.
-
Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.Ann Oncol. 2012 Mar;23(3):556-562. doi: 10.1093/annonc/mdr321. Epub 2011 Jul 6. Ann Oncol. 2012. PMID: 21734221 Review.
-
Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.Expert Rev Anticancer Ther. 2012 Jan;12(1):31-40. doi: 10.1586/era.11.187. Expert Rev Anticancer Ther. 2012. PMID: 22149430 Review.
Cited by
-
PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis.CNS Drugs. 2012 Mar 1;26(3):205-14. doi: 10.2165/11596970-000000000-00000. CNS Drugs. 2012. PMID: 22201341 Review.
-
Major clinical research advances in gynecologic cancer in 2010.J Gynecol Oncol. 2010 Dec 30;21(4):209-18. doi: 10.3802/jgo.2010.21.4.209. Epub 2010 Dec 31. J Gynecol Oncol. 2010. PMID: 21278881 Free PMC article.
-
A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).Int J Clin Oncol. 2019 Oct;24(10):1284-1291. doi: 10.1007/s10147-019-01471-5. Epub 2019 May 24. Int J Clin Oncol. 2019. PMID: 31127479 Clinical Trial.
References
-
- Ries LAG, Melbert D, Krapcho M, et al. Bethesda, MD: National Cancer Institute; 2008. [accessed June 25, 2009]. SEER Cancer Statistics Review, 1975–2004. Available at http://seer.cancer.gov/csr/1975_2005/
-
- Berek JS, Bertelsen K, Du Bois A, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol. 1999;10(suppl 1):87–92. - PubMed
-
- Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma in the platinum era: A meta-analysis. J Clin Oncol. 2002;20:1248–1259. - PubMed
-
- du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–1329. - PubMed
-
- Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gyncologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials